According to reports, Cadila Healthcare Ltd had earlier applied for the authorisation of the coronavirus vaccine ZyCoV-D on July 1, based on an efficacy rate of 66.6 per cent in a late-stage trial of more than 28,000 volunteers nationwide.
The vaccine by Cadila Healthcare, ZyCoV-D, would become the fifth vaccine cleared for use in the country after locally produced Covishield, Bharat Biotech's Covaxin, Russia's Sputnik V and the US-made Moderna. Moreover, it will become the world’s first DNA vaccine to get the nod in any country. In addition, this is the first time any vaccine has been tested in the adolescent population in the 12-18 age group in India.
ZyCoV-D, developed at the company's Vaccine Technology Centre in Ahmedabad, had earlier received permission from the Drug Controller General of India (DGCI) - Central Drugs Standard Control Organisation (CDSCO) to initiate phase I/II human clinical trials in India, Cadila Healthcare said in a regulatory filing.
According to reports, in animal studies, the vaccine was found to elicit a strong immune response in multiple animal species like mice, rats, guinea pigs and rabbits. In addition, the antibodies produced by the vaccine were able to completely neutralise the wild type virus in virus neutralisation assay indicating the protective potential of the vaccine candidate.
ALSO READ: No COVID-19 vaccination drive at TMC, KDMC and BMC centres today
Share
Tweet
